Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1485358
This article is part of the Research Topic Precision Oncology in Checkpoint Immunotherapy: Leveraging Predictive Biomarkers for Personalized Treatment View all 4 articles

Case Report: Therapeutic Response of Front-line Cadonilimab plus Chemotherapy on Patient with Advanced Lung Adenocarcinoma Harboring STK11 Genetic Aberration

Provisionally accepted
Du Feng Du Feng 1Huixin Jiang Huixin Jiang 1GengJia Chen GengJia Chen 1Wenhui Guan Wenhui Guan 1Lin Yi Lin Yi 1Yue Zhu Yue Zhu 1Yy F Yy F 1Gengda Huang Gengda Huang 1Bin He Bin He 1Junlong Tang Junlong Tang 1Yujie Tang Yujie Tang 1Jiyuan Zeng Jiyuan Zeng 1Wensheng Zhou Wensheng Zhou 1Jiayu Shi Jiayu Shi 2Zhanhong Xie Zhanhong Xie 1Ming Liu Ming Liu 1Xiaohong Xie Xiaohong Xie 1Xinqing Lin Xinqing Lin 1*Chengzhi Zhou Chengzhi Zhou 1*
  • 1 National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • 2 First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for frontline treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS). This case highlights the potential efficacy and feasibility of combining immunotherapy with chemotherapy in patients with STK11-mutant NSCLC. Additionally, we provide a review of recent advancements in research related to STK11 mutations in lung cancer as reported in the literature.

    Keywords: STK11 mutation, Lung Adenocarcinoma, case report, Cadonilimab, Front-line therapy

    Received: 23 Aug 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Feng, Jiang, Chen, Guan, Yi, Zhu, F, Huang, He, Tang, Tang, Zeng, Zhou, Shi, Xie, Liu, Xie, Lin and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xinqing Lin, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Chengzhi Zhou, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.